What does an estimated glomerular filtration rate of 45 mL/min/1.73 m² indicate and what management steps are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

eGFR 45 mL/min/1.73 m²: Classification and Management

An eGFR of 45 mL/min/1.73 m² indicates moderately reduced kidney function (CKD G3a) and requires immediate assessment of albuminuria to determine cardiovascular and kidney disease risk, followed by initiation of SGLT-2 inhibitors in most patients.

CKD Classification

An eGFR of 45 mL/min/1.73 m² places the patient in CKD category G3a (mildly to moderately decreased GFR: 45-59 mL/min/1.73 m²) 1. This represents a critical threshold where management decisions become heavily dependent on albuminuria status.

Risk Stratification

The next essential step is measuring the albumin-to-creatinine ratio (ACR) to complete risk stratification 2:

  • Moderate risk: eGFR 45-59 with ACR <3 mg/mmol (<30 mg/g)
  • High risk: eGFR 45-59 with ACR 3-30 mg/mmol (30-299 mg/g)
  • Very high risk: eGFR 45-59 with ACR >30 mg/mmol (≥300 mg/g)

This classification directly determines treatment intensity and monitoring frequency.

Core Management Recommendations

SGLT-2 Inhibitors

For patients with eGFR 45-59 and ACR <3 mg/mmol: Consider SGLT-2 inhibitor therapy (weak recommendation) 2.

For patients with eGFR 45-59 and ACR ≥3 mg/mmol: Strongly recommend SGLT-2 inhibitor initiation 2, 3. The 2024 KDIGO guideline provides high certainty evidence for overall survival benefit and reduced kidney failure risk in this population. SGLT-2 inhibitors should be continued even if eGFR subsequently drops below 20 mL/min/1.73 m² unless dialysis is initiated 3.

RAS Inhibition

Start ACE inhibitor or ARB if albuminuria is present 3:

  • Mandatory for ACR ≥30 mg/mmol (A3 category) - strong recommendation
  • Suggested for ACR 3-30 mg/mmol (A2 category) - conditional recommendation

Use the highest tolerated approved dose. Monitor serum creatinine and potassium within 2-4 weeks of initiation. Continue therapy even if creatinine rises up to 30% within 4 weeks, unless symptomatic hypotension or uncontrolled hyperkalemia develops 3.

Blood Pressure Management

Target office BP <120/80 mmHg if tolerated without symptoms of hypotension. This applies regardless of diabetes status when albuminuria is present 3.

Monitoring Schedule

Based on the 2022 Mayo Clinic diabetic kidney disease guideline 4:

  • eGFR 45-59 with ACR <3 mg/mmol (moderate risk): Monitor twice yearly
  • eGFR 45-59 with ACR 3-30 mg/mmol (high risk): Monitor twice yearly
  • eGFR 45-59 with ACR >30 mg/mmol (very high risk): Monitor 3 times yearly

Each visit should include serum creatinine, eGFR calculation, electrolytes (particularly potassium), and urine ACR.

Nephrology Referral

Consider nephrology referral for patients with eGFR 45-59 and ACR >30 mg/mmol, though this may be managed in primary care depending on local resources and expertise 4. Mandatory referral becomes necessary if eGFR drops below 30 mL/min/1.73 m² 5.

Medication Adjustments

At eGFR 45 mL/min/1.73 m²:

  • Metformin: Review use and consider risk-benefit; suspend if patient becomes acutely ill 5
  • Tetracyclines: Reduce dose; can exacerbate uremia 5
  • Antifungals: Reduce fluconazole maintenance dose by 50% 5
  • NSAIDs: Avoid prolonged therapy 5

Critical Pitfalls

Do not discontinue ACE inhibitors or ARBs solely because eGFR is 45 mL/min/1.73 m². These remain nephroprotective and should be continued unless specific contraindications develop (>30% creatinine rise, symptomatic hypotension, or refractory hyperkalemia) 3.

Do not delay SGLT-2 inhibitor initiation in patients with albuminuria. The 2024 BMJ guideline demonstrates moderate-to-high certainty evidence for mortality reduction and cardiovascular benefit, with the reversible eGFR dip upon initiation not being an indication to stop therapy 2.

Age considerations: While eGFR 45 mL/min/1.73 m² may represent normal age-related decline in adults >70 years 6, 7, the presence of albuminuria still mandates treatment as cardiovascular and mortality risks remain elevated regardless of age 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.